摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

agent lactone | 360778-69-4

中文名称
——
中文别名
——
英文名称
agent lactone
英文别名
(3R)-2,2-dimethyl-3-phenyl-3H-1,4-oxazin-6-one
agent lactone化学式
CAS
360778-69-4
化学式
C12H13NO2
mdl
——
分子量
203.241
InChiKey
AISCPSRYGCFAQP-LLVKDONJSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    298.6±43.0 °C(Predicted)
  • 密度:
    1.12±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    2
  • 重原子数:
    15
  • 可旋转键数:
    1
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.33
  • 拓扑面积:
    38.7
  • 氢给体数:
    0
  • 氢受体数:
    3

反应信息

  • 作为反应物:
    描述:
    agent lactone三乙胺三氟乙酸 作用下, 以 二氯甲烷 为溶剂, 反应 0.5h, 生成 methanesulfonic acid 6-(6,6-dimethyl-2-oxo-5-phenylmorpholin-3-yl)-2,4-dimethoxy-3-methylphenyl ester
    参考文献:
    名称:
    光学活性α-芳基甘氨酸的合成:具有新手性模板的立体选择性曼尼希型反应
    摘要:
    酚与从商业可得的苯基甘氨酸制备的亚胺内酯4的曼尼赫反应高立体选择性地生成α-芳基甘氨酸衍生物。该反应也适用于其他电子丰富的芳香化合物和芳基硼酸。这些加合物可以方便地转化为相应的光学活性α-芳基甘氨酸。
    DOI:
    10.1055/s-2001-15168
  • 作为产物:
    描述:
    左旋苯甘氨酸lead(IV) acetate甲醇氯化亚砜methyloxirane 作用下, 以 四氢呋喃甲苯乙腈 为溶剂, 生成 agent lactone
    参考文献:
    名称:
    光学活性α-芳基甘氨酸的合成:具有新手性模板的立体选择性曼尼希型反应
    摘要:
    酚与从商业可得的苯基甘氨酸制备的亚胺内酯4的曼尼赫反应高立体选择性地生成α-芳基甘氨酸衍生物。该反应也适用于其他电子丰富的芳香化合物和芳基硼酸。这些加合物可以方便地转化为相应的光学活性α-芳基甘氨酸。
    DOI:
    10.1055/s-2001-15168
点击查看最新优质反应信息

文献信息

  • Total Synthesis of Ecteinascidin 743
    作者:Atsushi Endo、Arata Yanagisawa、Masanao Abe、Shigemitsu Tohma、Toshiyuki Kan、Tohru Fukuyama
    DOI:10.1021/ja026216d
    日期:2002.6.1
    A straightforward synthesis of ecteinascidin 743 was accomplished from readily available l-glutamic acid as a single chiral source. Our novel synthesis features a concise and convergent approach for construction of the B-ring, consisting of a sequence involving a stereoselective Heck reaction between a diazonium salt and an enamide, oxidative cleavage of the resulting alkene, and intramolecular ortho
    海鞘素 743 的直接合成是从容易获得的 l-谷氨酸作为单一手性来源完成的。我们的新合成具有构建 B 环的简洁和收敛的方法,包括一个序列,涉及重氮盐和烯酰胺之间的立体选择性 Heck 反应、所得烯烃的氧化裂解以及苯酚的分子内邻位取代醛。
  • Synthetic Studies on (+)-Naphthyridinomycin:  Stereoselective Synthesis of the Tetracyclic Core Framework
    作者:Kazuki Mori、Kentaro Rikimaru、Toshiyuki Kan、Tohru Fukuyama
    DOI:10.1021/ol048857e
    日期:2004.9.1
    [reaction: see text] The stereoselective synthesis of the tetracyclic intermediate 21 for (+)-naphthyridinomycin (1) has been accomplished. The convergent synthesis used the Ugi 4CC reaction with the amine derivative 10. The key features of the stereoselective synthesis of 21 were the intramolecular Mizoroki-Heck reaction, an aromatic-aldehyde cyclization, and a stereoselective hydroboration.
    [反应:见正文]已经完成了对(+)-萘啶霉素(1)的四环中间体21的立体选择性合成。会聚合成使用Ugi 4CC反应与胺衍生物10进行。21的立体选择性合成的关键特征是分子内Mizoroki-Heck反应,芳族醛环化和立体选择性硼氢化。
  • Preparation for natural product trabectedin
    申请人:CE Pharm Co., Ltd.
    公开号:US11339179B2
    公开(公告)日:2022-05-24
    The present invention provides a preparation method for a natural product Trabectedin. Specifically, the present invention provides a preparation method for Et-743. In the method, tyrosine is used as an initial substrate, and after 26 steps of reaction, the Et-743 is synthesized. Raw materials and agents used in the synthetic route can all easily be obtained, reaction conditions are relatively mild, and preparation in large scale can be implemented.
    本发明提供了一种天然产物 Trabectedin 的制备方法。具体而言,本发明提供了一种 Et-743 的制备方法。在该方法中,以酪氨酸为初始底物,经过26步反应,合成Et-743。合成路线中使用的原料和制剂都很容易获得,反应条件相对温和,可以实现大规模制备。
  • Method For Total Synthesis Of Ecteinascidins And Intermediate Compounds Thereof
    申请人:FUKUYAMA Tohru
    公开号:US20090036673A1
    公开(公告)日:2009-02-05
    An intermediate compound for total synthesis of ecteinascidins comprising, a compound represented by general formula 2 having thioether group at C4 site, and the substituent R 2 of N 12 site is trichloroethoxicarbonyl (Troc) to which various substituents can be introduced by mild condition, further having 10 members ring structure which can be converted to a ring of other numbered members.
  • PREPARATION FOR NATURAL PRODUCT TRABECTEDIN
    申请人:CE Pharm Co., Ltd.
    公开号:US20210163500A1
    公开(公告)日:2021-06-03
    The present invention provides a preparation method for a natural product Trabectedin. Specifically, the present invention provides a preparation method for Et-743. In the method, tyrosine is used as an initial substrate, and after 26 steps of reaction, the Et-743 is synthesized. Raw materials and agents used in the synthetic route can all easily be obtained, reaction conditions are relatively mild, and preparation in large scale can be implemented.
查看更多

同类化合物

乙基6H-1,2-恶嗪-3-羧酸酯 6-乙氧基-6H-1,2-恶嗪-3-甲醛 6-乙氧基-3-苯基-6H-1,2-恶嗪 5-甲氧基-3,6-二氢-2H-[1,4]恶嗪 5-乙氧基-3,6-二氢-2H-1,4-恶嗪 5,6-二氢-2H-1,4-恶嗪-3-胺 4H-1,4-恶嗪 3H-咪唑并[2,1-c][1,4]恶嗪 3-甲基-5-苯基-2H-1,4-恶嗪 3,5-二苯基-2H-1,4-恶嗪 3,5,5,6-四甲基-5,6-二氢-2H-1,4-恶嗪-2-酮 2H-[1,4]恶嗪并[3,4-b][1,3]恶嗪 2H-1,4-恶嗪 2H-1,4-噁嗪-2-酮,5,6-二氢-5-(1-甲基乙基)-3-苯基-,(S)- 2H-1,4-噁嗪-2-酮,3-(1,1-二甲基乙基)-5,6-二氢-5-苯基-,(R)- 2H-1,3-恶嗪 2H-1,2-恶嗪 2-(二甲基氨基)-4-苯基-4H-1,3-恶嗪-5-甲醛 (5S)-5,6-二氢-6,6-二甲基-5-苯基-2H-1,4-恶嗪-2-酮 6-amino-4-phenyl-4H-1,2-oxazine-3,5-dicarbonitrile (2S,5R)-2-hydroxy-5,6-dihydro-2-ethyl-3-methyl-5-phenyl-2H-1,4-oxazine (2S,5R)-2-hydroxy-5,6-dihydro-3-methyl-2,5-diphenyl-2H-1,4-oxazine (2S,5R,6R)-2-hydroxy-5,6-dihydro-2,3-diethyl-5-methyl-6-phenyl-2H-1,4-oxazine (2S,5R)-2-hydroxy-5,6-dihydro-2,3-diethyl-5-phenyl-2H-1,4-oxazine (2S,5S,6R)-2-hydroxy-5,6-dihydro-2,3,5-trimethyl-6-phenyl-2H-1,4-oxazine (2S,5S,6R)-2-hydroxy-5,6-dihydro-2,3-diethyl-5-methyl-6-phenyl-2H-1,4-oxazine (2S,5S,6R)-2-hydroxy-5,6-dihydro-3,5-dimethyl-6-phenyl-2-propyl-2H-1,4-oxazine (Z)-methyl-2-((R)-5-(2-(methylthio)ethyl)-3-oxomorpholin-2-ylidene)acetate (Z)-methyl-2-((R)-5-benzyl-3-oxomorpholin-2-ylidene)acetate (2R,5R,6S)-5,6-dihydro-3,6-diphenyl-2-hydroxy-5-methyl-1,4-oxazine (2S,5R,6R)-2-hydroxy-5,6-dihydro-2-ethyl-3,5-dimethyl-6-phenyl-2H-1,4-oxazine (2S,5S,6R)-2-hydroxy-5,6-dihydro-2-ethyl-3,5-dimethyl-6-phenyl-2H-1,4-oxazine 2-heptafluoropropyl-3-trifluoromethyl-5,6-dihydro-1,4-oxazin-2-ol (2S,5R,6R)-2-hydroxy-5,6-dihydro-3,5-dimethyl-2,6-diphenyl-2H-1,4-oxazine (2S,5S,6R)-2-hydroxy-5,6-dihydro-3,5-dimethyl-2,6-diphenyl-2H-1,4-oxazine 6H-1,2-Oxazine 4,4,6-Trimethyl-2-dimethylamino-4H-1,3-oxazine 3-(chloromethyl)-5,6-dihydro-5,5-dimethyl-1,4-oxazin-2-one 3-(acetoxymethyl)-5,6-dihydro-5,5-dimethyl-1,4-oxazin-2-one 6-Butyl-2,4-diphenyl-4H-[1,3]oxazine 2-methyl-2,4,6-triphenyl-2H-1,3-oxazine (S)-2,4,6-triphenyl-4H-1,3-oxazine 2-Isopropenyl-6-phenyl-6-piperidin-1-yl-6H-[1,3]oxazin-4-ol 5-methyl-6-perhydroxy-3-phenyl-6H-1,2-oxazine 5-methyl-3-phenyl-6-(prop-2-yn-1-oxy)-6H-1,2-oxazine 2,2,3,3,6,6-Hexafluoro-5-(2,2,2-trifluoro-1-trifluoromethyl-ethoxy)-3,6-dihydro-2H-[1,4]oxazine 4,4-Dimethyl-2-phenyl-1,3-oxazine (R)-3-(but-3-enyl)-5-phenyl-5,6-dihydro-2H-1,4-oxazin-2-one Acetic acid 3,5-dimethyl-6-oxo-3,6-dihydro-2H-[1,4]oxazin-3-ylmethyl ester (2R,5R)-3-methyl-5-phenyl-2-(trifluoromethyl)-5,6-dihydro-2H-1,4-oxazin-2-ol